Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

pharmanewsdaily- December 12, 2019 0

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More

ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib

pharmanewsdaily- November 23, 2019 0

ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase ... Read More

Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment

pharmanewsdaily- February 3, 2019 0

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer's lung cancer drug, Vizimpro (dacomitinib), ... Read More

Merck secures EC approval for Keytruda in combination therapy for lung cancer

pharmanewsdaily- September 12, 2018 0

Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More

123434 / 34 Posts